A Randomized-Withdrawal Phase 3 Study Evaluating the Safety and Efficacy of Oral Nalfurafine HCl (AC-820)in Subjects on Hemodialysis With Uremic Pruritus (Renal Itch)

NCT00793156 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

350

Enrollment

INDUSTRY

Sponsor class

Conditions

Uremic Pruritus

Interventions

DRUG: Nalfurafine HCl 2.5 µg
DRUG: Nalfurafine HCl 5.0 µg
OTHER: Placebo

Sponsor

Acologix, Inc.